(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/126604 A1

(51) International Patent Classification:
A61K 47/55 (2017.01) *A61K 47/64* (2017.01)
A61K 47/59 (2017.01) *A61K 47/54* (2017.01)

(21) International Application Number:
PCT/EP2019/084190

(22) International Filing Date:
09 December 2019 (09.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2022283	21 December 2018 (21.12.2018)	NL
2023468	10 July 2019 (10.07.2019)	NL
2023568	25 July 2019 (25.07.2019)	NL

(71) Applicants: **SAPREME TECHNOLOGIES B.V.** [NL/NL]; Professor Bronkhorstlaan 10 G 92, 3723 MB Bilthoven (NL). **CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN** [DE/DE]; Charité-platz 1, 10117 Berlin (DE).

(72) Inventors: **POSTEL, Ruben**; Yalelaan 62, LSI, Room 2.09, 3584 CM Utrecht (NL). **FUCHS, Hendrik**; Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie Charité - Universitätsmedizin, Berlin Campus, Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin (DE).

(74) Agent: **NEDERLANDSCH OCTROOIBUREAU**; P.O. Box 29720, 2502 LS The Hague (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2020/126604 A1

(54) Title: SAPONIN CONJUGATES

(57) Abstract: The invention relates to a therapeutic combination for use as a medicament, wherein the therapeutic combination comprises: (a) a first pharmaceutical composition comprising a first proteinaceous molecule and at least one saponin covalently bound to said first proteinaceous molecule; and (b) a second pharmaceutical composition comprising a second proteinaceous molecule, comprising an effector moiety, wherein the binding site of the first proteinaceous molecule and the binding site of the second proteinaceous molecule are the same. The invention also relates to the first pharmaceutical composition for use as a medicament. The invention also relates to the first pharmaceutical composition, further comprising the second proteinaceous molecule. The invention also relates to the first pharmaceutical composition, further comprising the second proteinaceous molecule, for use as a medicament. Furthermore, the invention relates to the first pharmaceutical composition, further comprising the second proteinaceous molecule, for use in the treatment or prophylaxis of cancer in a patient in need thereof.